Hans Lundqvist

Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts

Mortensen, Anja; Berglund, Hanna; Jha, Preeti; Stenman, Adam et al.

Ingår i Molecular Cancer Therapeutics, s. 753-762, 2025

• DOI för Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts
• Ladda ner fulltext (pdf) av Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts

Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy

Mortensen, Anja; Spiegelberg, Diana; Haylock, Anna-Karin; Lundqvist, Hans et al.

Ingår i International Journal of Oncology, s. 1875-1885, 2018

• DOI för Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
• Ladda ner fulltext (pdf) av Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 970-988, 2018

• DOI för Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
• Ladda ner fulltext (pdf) av Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification.

Velikyan, Irina; Sundin, Anders; Sörensen, Jens; Lubberink, Mark et al.

Ingår i Journal of Nuclear Medicine, s. 204-10, 2014

• DOI för Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification.

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

Sandström, Mattias; Garske-Román, Ulrike; Granberg, Dan; Johansson, Silvia et al.

Ingår i Journal of Nuclear Medicine, s. 33-41, 2013

• DOI för Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts

Mortensen, Anja; Berglund, Hanna; Jha, Preeti; Stenman, Adam et al.

Ingår i Molecular Cancer Therapeutics, s. 753-762, 2025

• DOI för Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts
• Ladda ner fulltext (pdf) av Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts

Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy

Mortensen, Anja; Spiegelberg, Diana; Haylock, Anna-Karin; Lundqvist, Hans et al.

Ingår i International Journal of Oncology, s. 1875-1885, 2018

• DOI för Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
• Ladda ner fulltext (pdf) av Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 970-988, 2018

• DOI för Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
• Ladda ner fulltext (pdf) av Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification.

Velikyan, Irina; Sundin, Anders; Sörensen, Jens; Lubberink, Mark et al.

Ingår i Journal of Nuclear Medicine, s. 204-10, 2014

• DOI för Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification.

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

Sandström, Mattias; Garske-Román, Ulrike; Granberg, Dan; Johansson, Silvia et al.

Ingår i Journal of Nuclear Medicine, s. 33-41, 2013

• DOI för Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein

Orlova, Anna; Jonsson, Andreas; Rosik, Daniel; Lundqvist, Hans et al.

Ingår i Journal of Nuclear Medicine, s. 961-968, 2013

• DOI för Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein
• Ladda ner fulltext (pdf) av Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein

Dosimetry for gadolinium neutron capture therapy (GdNCT)

Enger, Shirin A.; Giusti, Valerio; Fortin, Marc-Andre; Lundqvist, Hans et al.

Ingår i Radiation Measurements, s. 233-240, 2013

• DOI för Dosimetry for gadolinium neutron capture therapy (GdNCT)

Comparative Biodistribution and Radiation Dosimetry of Ga-68-DOTATOC and Ga-68-DOTATATE in Patients with Neuroendocrine Tumors

Sandström, Mattias; Velikyan, Irina; Garske-Roman, Ulrike; Sörensen, Jens et al.

Ingår i Journal of Nuclear Medicine, s. 1755-1759, 2013

• DOI för Comparative Biodistribution and Radiation Dosimetry of Ga-68-DOTATOC and Ga-68-DOTATATE in Patients with Neuroendocrine Tumors

Biological effective doses in 300 patients undergoing therapy with Lu-177-octreotate

Sandström, Mattias; Garske-Roman, Ulrike; Granberg, Dan; Eriksson, B. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2013

Lessons on Tumour Response: Imaging during Therapy with Lu-177-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma

Garske, Ulrike; Sandström, Mattias; Johansson, Silvia; Granberg, Dan et al.

Ingår i Theranostics, s. 459-471, 2012

• DOI för Lessons on Tumour Response: Imaging during Therapy with Lu-177-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma

Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting Nuclisome-particles

Gedda, Lars; Fondell, Amelie; Lundqvist, Hans; Park, John et al.

Ingår i Journal of Nuclear Medicine, s. 480-487, 2012

• DOI för Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting Nuclisome-particles

Inter-observer variability of absorbed dose estimates to the kidney in patients with neuroendocrine tumours receiving Lu-177-Octreotate therapy

Sandstrom, M. P.; Karlberg, A.; Garske, Ulrike; Lubberink, Mark et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2012

Exploring Co-57 as a new isotope for brachytherapy applications

Enger, Shirin A.; Lundqvist, Hans; D'Amours, Michel; Beaulieu, Luc

Ingår i Medical physics (Lancaster), s. 2342-2345, 2012

• DOI för Exploring Co-57 as a new isotope for brachytherapy applications

Evaluating abdominal oedema during experimental sepsis using an isotope technique

Lattuada, Marco; Maripuu, Enn; Hård af Segerstad, Carl; Lundqvist, Hans et al.

Ingår i Clinical Physiology and Functional Imaging, s. 197-204, 2012

• DOI för Evaluating abdominal oedema during experimental sepsis using an isotope technique

Improved Tumor-to-Organ Ratios of a Novel ⁶⁷Ga-Human Epidermal Growth Factor Radionuclide Conjugate with Preadministered Antiepidermal Growth Factor Receptor Affibody Molecules

Sandström, Karl; Haylock, Anna-Karin; Velikyan, Irina; Spiegelberg, Diana et al.

Ingår i Cancer Biotherapy and Radiopharmaceuticals, s. 593-601, 2011

• DOI för Improved Tumor-to-Organ Ratios of a Novel ⁶⁷Ga-Human Epidermal Growth Factor Radionuclide Conjugate with Preadministered Antiepidermal Growth Factor Receptor Affibody Molecules

Minor changes in effective half-life during fractionated ¹⁷⁷Lu-Octreotate therapy

Garske, Ulrike; Sandström, Mattias; Johansson, Silvia; Sundin, Anders et al.

Ingår i Acta Oncologica, s. 86-96, 2011

• DOI för Minor changes in effective half-life during fractionated ¹⁷⁷Lu-Octreotate therapy

In vivo binding of [⁶⁸Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass

Velikyan, Irina; Sundin, Anders; Eriksson, Barbro; Lundqvist, Hans et al.

Ingår i Nuclear Medicine and Biology, s. 265-275, 2010

• DOI för In vivo binding of [⁶⁸Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass

Imaging biomarkers for diagnosis and quantification with positron emission tomography: assistance to therapy

Velikyan, Irina; Sundin, Anders; Eriksson, Barbro; Lundqvist, Hans et al.

Ingår i Nuclear Medicine and Biology, s. 724-724, 2010

• DOI för Imaging biomarkers for diagnosis and quantification with positron emission tomography: assistance to therapy

Individualized dosimetry in patients undergoing therapy with Lu-177-DOTA-D-Phe(1)-Tyr(3)-octreotate

Sandström, Mattias; Garske, Ulrike; Granberg, Dan; Sundin, Anders et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 212-225, 2010

• DOI för Individualized dosimetry in patients undergoing therapy with Lu-177-DOTA-D-Phe(1)-Tyr(3)-octreotate

Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF

Kareem, Heewa; Sandström, Karl; Elia, Ronny; Gedda, Lars et al.

Ingår i Tumor Biology, s. 79-87, 2010

• DOI för Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF

The influence of Bz-DOTA and CHX-AaEuro(3)-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for In-114m-mediated targeting therapy

Tolmachev, Vladimir; Wallberg, Helena; Andersson, Karl; Wennborg, Anders et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 1460-1468, 2009

• DOI för The influence of Bz-DOTA and CHX-AaEuro(3)-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for In-114m-mediated targeting therapy

Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinical characterization of an 111In-labeled monoclonal antibody

Sandström, Karl; Nestor, Marika; Ekberg, Tomas; Engström, Mats et al.

Ingår i Tumor Biology, s. 137-144, 2008

• DOI för Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinical characterization of an 111In-labeled monoclonal antibody

Characterization of In-111 and Lu-177-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay

Nestor, Marika; Andersson, Karl; Lundqvist, Hans

Ingår i Journal of Molecular Recognition, s. 179-183, 2008

• DOI för Characterization of In-111 and Lu-177-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay

Cross-fire doses from β-emitting radionuclides in targeted radiotherapy: A theoretical study based on experimentally measured tumor characteristics

Enger, Shirin Abbasinejad; Hartman, Torbjörn; Carlsson, Jörgen; Lundqvist, Hans

Ingår i Physics in Medicine and Biology, s. 1909-1920, 2008

• DOI för Cross-fire doses from β-emitting radionuclides in targeted radiotherapy: A theoretical study based on experimentally measured tumor characteristics

Real-time viability assay based on ⁵¹Cr retention in adherent cells

Vennström, Lina; Bysell, Camilla; Björkelund, Hanna; Lundqvist, Hans et al.

Ingår i BioTechniques, s. 237-240, 2008

• DOI för Real-time viability assay based on ⁵¹Cr retention in adherent cells

Targeting EGFR and HER2 with 211At-labeled molecules: unexpected and expected dose-effect relations in cultured tumor cells

Carlsson, Jörgen; Steffen, Ann-Charlott; Sundberg, Åsa L.; Vikström, Mikael et al.

Ingår i Current radiopharmaceuticals, s. 225-233, 2008

Genotoxic hazard of radiopharmaceuticals in humans: chemical and radiation aspects coupled to microdosing

Lundqvist, Hans; Antoni, Gunnar; Långström, Bengt

Ingår i European Journal of Clinical Pharmacology, s. 641-645, 2007

• DOI för Genotoxic hazard of radiopharmaceuticals in humans: chemical and radiation aspects coupled to microdosing

Food interaction of oral uptake of iron: a clinical trial using 59Fe

Lundqvist, Hans; Sjöberg, Folke

Ingår i Arzneimittel-Forschung, s. 401-416, 2007

[Lu-177]pertuzumab: Experimental therapy of HER-2-expressing xenografts

Persson, Mikael; Gedda, Lars; Lundqvist, Hans; Tolmachev, Vladimir et al.

Ingår i Cancer Research, s. 326-331, 2007

• DOI för [Lu-177]pertuzumab: Experimental therapy of HER-2-expressing xenografts

Biodistribution of At-211-Labeled humanized monoclonal antibody A33

Almqvist, Ylva; Steffen, Ann-Charlott; Lundqvist, Hans; Jensen, Holger et al.

Ingår i Cancer Biotherapy and Radiopharmaceuticals, s. 480-487, 2007

• DOI för Biodistribution of At-211-Labeled humanized monoclonal antibody A33

Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors

Orlova, Anna; Rosik, Daniel; Sandström, Mattias; Lundqvist, Hans et al.

Ingår i The Quarterly Journal of Nuclear Medicine and Molecular Imaging, s. 314-323, 2007

Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule

Tolmachev, Vladimir; Orlova, Anna; Pehrson, Rikard; Galli, Joakim et al.

Ingår i Cancer Research, s. 2773-2782, 2007

• DOI för Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule

Biodistribution of 211At labeled HER-2 binding affibody molecules in mice

Steffen, Ann-Charlott; Almqvist, Ylva; Chyan, Ming-Kuan; Lundqvist, Hans et al.

Ingår i Oncology Reports, s. 1141-1147, 2007

Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies

Fortin, Marc-André; Salnikov, Alexei V.; Nestor, Marika; Heldin, Nils-Erik et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 1376-1387, 2007

• DOI för Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies

An Aminoacridine Derivative for Radionuclide Therapy: Dna-Binding Properties Studied in a Novel Cell-Free in vitro Assay

Kullberg, E-B.; Stenerlöw, B.; Ghirmait, Senait; Lundqvist, Hans et al.

Ingår i Int. J. Onc., s. 1355-1360, 2005

Synthesis and radioiodination of some 9-aminoacridine derivatives for potential use in radionuclide therapy

Ghirmai, Senait; Mume, Eskender; Lundqvist, Hans; Tolmachev, Vladimir et al.

Ingår i Journal of labelled compounds & radiopharmaceuticals, s. 855-871, 2005

• DOI för Synthesis and radioiodination of some 9-aminoacridine derivatives for potential use in radionuclide therapy

In vitro characterization of 211 At-labeled antibody A33: a potential therapeutic agent against metastatic colorectal carcinoma

Almqvist, Ylva; Orlova, Anna; Sjöström, Anna; Jensen, Holger J. et al.

Ingår i Cancer Biotherapy and Radiopharmaceuticals, s. 514-523, 2005

• DOI för In vitro characterization of 211 At-labeled antibody A33: a potential therapeutic agent against metastatic colorectal carcinoma

Radionuklidterapi - möjlig väg mot bättre behandling av cancer: Hindret är bristen på kommersiellt tillgängliga nuklider i kliniken

Lundqvist, Hans; Carlsson, Jörgen; Gedda, Lars; Tolmachev, Vladimir et al.

Ingår i Läkartidningen, s. 1000-1006, 2004

Targeting against epidermal growth factor receptors: Cellular processing of astatinated EGF after binding to cultured carcinoma cells

Orlova, Anna; Sjöström, Anna; Lebeda, Ondrej; Lundqvist, Hans et al.

Ingår i Anticancer Research, s. 4035-4042, 2004

Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI)

Bruskin, Alexander; Sivaev, Igor; Persson, Mikael; Lundqvist, Hans et al.

Ingår i Nuclear Medicine and Biology, s. 205-11, 2004

HER2 expression in breast cancer primary tumours and corresponding metastases: Original data and literature review

Carlsson, Jörgen; Nordgren, Hans; Sjöström, J.; Wester, Kenneth et al.

Ingår i British Journal of Cancer, s. 2344-2348, 2004

Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT

Sandström, Mattias; Tolmachev, Vladimir; Kairemo, Kalevi; Lundqvist, Hans et al.

Ingår i Physics in Medicine and Biology, s. 5419-32, 2004

• DOI för Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT

A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy: availability of suitable radionuclides

Tolmachev, Vladimir; Carlsson, Jörgen; Lundqvist, Hans

Ingår i Acta Oncologica, s. 264-75, 2004

Preparation, radioiodination, and in vitro evaluation of a nido-carborane-dextran conjugate, a potential residualizing label for tumor targeting proteins and peptides

Tolmachev, Vladimir; Bruskin, Alexander; Sjöberg, Stefan; Carlsson, Jörgen et al.

Ingår i Journal of Radioanalytical and Nuclear Chemistry, s. 107-112, 2004

• DOI för Preparation, radioiodination, and in vitro evaluation of a nido-carborane-dextran conjugate, a potential residualizing label for tumor targeting proteins and peptides

Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives

Ghirmai, Senait; Mume, Eskender; Henssen, Cecile; Ghaneolhusseini, Hadi et al.

Ingår i European Journal of Organic Chemistry, s. 3719-3725, 2004

• DOI för Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives

Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB1 H11: Aspects of labelling chemistry in aqueous solution using Chloramine-T

Orlova, Anna; Sivaev, I.; Sjöberg, Stefan; Lundqvist, Hans et al.

Ingår i Radiochimica Acta, s. 311, 2004

Pharmacokinetics and red cell utilization of ⁵²Fe/⁵⁹Fe-labelled iron polymaltose in anaemic patients using positron emission tomography

Beshara, Soheir; Sörensen, Jens; Lubberink, Mark; Tolmachev, Vladimir et al.

Ingår i British Journal of Haematology, s. 853-859, 2003

• DOI för Pharmacokinetics and red cell utilization of ⁵²Fe/⁵⁹Fe-labelled iron polymaltose in anaemic patients using positron emission tomography

Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography

Beshara, Soheir; Sörensen, Jens; Lubberink, Mark; Tolmachev, Vladimir et al.

Ingår i British Journal of Haematology, s. 853-859, 2003

• DOI för Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography

A miniature X-ray fluorescence set-up

Ribbing, Carolina; Andersson, Marit; Hjort, Klas; Lundqvist, Hans

Ingår i Review of Scientific Instruments, s. 3423-3428, 2003

Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33: Implications for in vivo dosimetry

Orlova, Anna; Höglund, Johanna; Lubberink, Mark; Lebeda, Ondrej et al.

Ingår i Cancer Biotherapy and Radiopharmaceuticals, s. 385-96, 2002

• DOI för Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33: Implications for in vivo dosimetry

Radiobromination of closo-dodecaborate anion. Aspects of labelling chemistry in aqueous solutions using Chloramine-T

Tolmachev, Vladimir; Bruskin, Alexander; Sivaev, Igor; Lundqvist, Hans et al.

Ingår i Radiochimica Acta, s. 229-235, 2002

Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET

Höglund, Johanna; Tolmachev, Vladimir; Orlova, Anna; Lundqvist, Hans et al.

Ingår i Nuclear Medicine and Biology, s. 837-43, 2000

• DOI för Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET

Closo-dodecaborate(2-)anion as a potential prosthetic group for attachment of astatine to proteins: Aspects of the labelling chemistry with Chloramine -T

Orlova, Anna; Lebeda, Ondrej; Tolmachev, Vladimir; Sjöberg, Stefan et al.

Ingår i Journal of labelled compounds & radiopharmaceuticals, s. 251-260, 2000

Conjugate chemistry and cellular processing of EGF-dextran

Carlsson, Jörgen; Blomquist, Erik; Gedda, Lars; Liljegren, Åsa et al.

Ingår i Acta Oncologica, s. 313-321, 1999

Gamma camera imaging of platinum in tumours and tissues of patientsatin.

Areberg, J; Bjorkman, S; Einarsson, L; Frankenberg, B et al.

Ingår i Acta Oncol., s. 221, 1999

Adjuvant 131I-anti-CEA-antibody radioimmunotherapy inhibits the development of experimental colonic carcinoma liver metastases

Mahteme, Haile; Lövqvist, A; Graf, Wilhelm; Lundqvist, Hans et al.

Ingår i Anticancer Research, s. 843-848, 1998

The Auger effect in molecular targeting therapy.

Lundqvist, Hans; Stenerlöw, Bo; Gedda, Lars

Ingår i Targeted radionuclide tumor therapy., s. 195-214, Springer, 2008

• DOI för The Auger effect in molecular targeting therapy.

Effect of ionizing radiation on the labeling of closo-dodecaborate(2-) anion with 125I

Lebeda, Ondrej; Orlova, Anna; Tolmachev, Vladimir; Lundqvist, Hans et al.

Ingår i Contemporary Boron Chemistry, Royal Society of Medicine Press, 2000

• DOI för Effect of ionizing radiation on the labeling of closo-dodecaborate(2-) anion with 125I

Cellular processing of indirectly astatinated and iodinated mAb A33 in SW1222 cultured cells

Orlova, Anna; Sjöström, Anna; Ericson, A.; Lebeda, Ondrej et al.

Ingår i Journal of labelled compounds & radiopharmaceuticals, 2001

• DOI för Cellular processing of indirectly astatinated and iodinated mAb A33 in SW1222 cultured cells

Cellular processing of ¹²⁵I- and ¹¹¹in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells

Orlova, Anna; Bruskin, Alexander; Sjöström, Anna; Lundqvist, Hans et al.

Ingår i Nuclear Medicine and Biology, s. 827-835, 2000

• DOI för Cellular processing of ¹²⁵I- and ¹¹¹in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells